DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients

Information source: Sanofi
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Infection; Febrile Neutropenia

Intervention: Teicoplanin (Drug); Vancomycin (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Sanofi

Official(s) and/or principal investigator(s):
Edibe Taylan, Study Director, Affiliation: Sanofi


The aim of the study is to evaluate the efficacy and safety of Teicoplanin versus Vancomycin as part of the initial antibiotic regimen in the therapy of patients with fever and neutropenia .

Clinical Details

Official title: Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: The primary efficacy parameter will be the Response

Secondary outcome: Safety will be assessed for all randomized patients who received at least one dose


Minimum age: 2 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Will initiate study drug treatment in the hospital;

- Has a life expectancy exc. 1 month. Is male or a non-pregnant, non-lactating female,

who is post-menopausal, surgically sterilized; or has been using one or more birth control methods for at least two months prior to study entry.

- Effective contraception must continue for at least 30 days after treatment

discontinuation; Exclusion Criteria:

- Has a history of suspected or documented Type I hypersensitivity reaction (e. g.

anaphylactic or anaphylactoid shock, respiratory distress from bronchospasm or rash) to glycopeptides (vancomycin or teicoplanin), aminoglycosides, b-lactams or cephalosporins

- Has renal dysfunction requiring dialysis ;

- Has neutropenia associated with a syndrome that is not generally thought to be

associated with a high risk of bacterial infection (e. g., chronic benign neutropenia);

- Is in blast crisis of chronic myeloid leukemia;

- Has a known underlying immunocompromising disease likely to interfere with the

evaluation of therapeutic response, such as infection with human immunodeficiency virus (HIV) ;

- Had isolation and identification of a specific pathogen suspected to be responsible

for fever ;Has documented colonization with vancomycin-resistant Enterococcus faecium or with Enterococcus faecalis

- Had received more than one dose of a systemic (whether oral or parenteral) antibiotic

within 3 calendar days preceding the initial therapy for this episode of fever;

- Has received oral vancomycin for prophylaxis of Gram-positive infection;

- Requires addition of anti-viral, anti-anaerobic or anti-fungal coverage at the same

time as study medication; however, antiviral or antifungal prophylaxis is allowed, provided that it is not started at the same time than study medication.

- Has suspected, invasive fungal disease (e. g. image of necrotic pneumonia),

peri-rectal infection, liver abscess, or necrotizing enterocolitis (typhlitis).

- Had a negative serum or urine laboratory pregnancy test (for all women except those

post-menopausal or surgically sterilized).

- The patient has one of the following: Leukemia, lymphoma, Hodgkin's disease, solid

tumors or who had undergone bone marrow transplantation (for any reason)

- Had neutropenia at the time of initiation of initial empiric antibiotic therapy,

defined as <500 neutrophils/mm3 of blood; or if ³500 but <1,000 neutrophils/mm3 and expected to fall below 500 neutrophils/mm3 within 48 hours.

- Has at least one of the following conditions:

- clinically obvious, serious catheter-related infections. For a patient with

documented catheter-related infection due to an organism other than coagulase negative staphylococci, the catheter has been removed within 24 hours of identification (removal over a guidewire is permitted).

- Intensive chemotherapy that produces substantial mucosal damage (i. e., high-dose

cytarabine (> 1 g/m2/day, which increases the risk for penicillin resistant streptococcal infections, particularly those due to viridans streptococci);

- prophylaxis with quinolones before the onset of the febrile episode; known

colonization with pneumococci that are resistant to penicillin and - cephalosporins

or methicillin-resistant S. aureus; a blood culture positive for gram-positive bacteria before final identification and susceptibility

Locations and Contacts

Sanofi aventis administrative office, Istanbul, Turkey
Additional Information

Starting date: January 2005
Last updated: March 5, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017